Skip to main content

Table 1 Characteristics of medication dataset at baseline. Only the time up to the first SRC is considered

From: ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

 

Patients with SRC (N = 102)

Patients without SRC (N = 7546)

Median # or risk difference (95% CI)

P value

Median (IQR) or no. of patients (%)

Age (years)

57.3 (48.0 to 67.9)

56.4 (46.0 to 65.7)

1.3 (− 1.3 to 3.9)

0.36

Sex (female)

80/102 (78%)

6484/7546 (86%)

− 7% (− 16 to 1%)

0.031

Time between onset of scleroderma and inclusion (y)*

5.0 (1.9 to 10.9)

7.0 (3.1 to 13.2)

− 1.3 (− 2.5 to − 0.3)

0.019

Extent of skin involvement

0.005

 No skin involvement

4/100 (4%)

306/7312 (4%)

  

 Only sclerodactyly

11/100 (11%)

785/7312 (11%)

  

 Limited cutaneous involvement

41/100 (41%)

4151/7312 (57%)

  

 Diffuse cutaneous involvement

44/100 (44%)

2070/7312 (28%)

  

Glucocorticoids

37/90 (41%)

2437/6644 (37%)

4% (− 6 to 15%)

0.39

Dose at baseline (if > 0), mg

7.5 (5.0 to 10.0)

5.0 (5.0 to 10.0)

0.0 (0.0 to 2.0)

0.16

Glucocorticoids > 10 mg

5/90 (6%)

295/6644 (4%)

1% (− 4 to 6%)

0.61

Glucocorticoids > 15 mg

3/90 (3%)

171/6644 (3%)

1% (− 3 to 4%)

0.65

ACE inhibitors

34/96 (35%)

1299/7163 (18%)

17% (8 to 27%)

< 0.001

Angiotensin receptor blocker

6/96 (6%)

654/7150 (9%)

− 3% (− 8 to 2%)

0.33

Calcium channel blockers

50/96 (52%)

3763/7178 (52%)

− 0% (− 10 to 10%)

0.95

Endothelin receptor antagonist

12/85 (14%)

727/6165 (12%)

2% (− 5 to 10%)

0.51

PDE5 inhibitors

6/91 (7%)

321/6649 (5%)

2% (− 3 to 7%)

0.44

  1. *Missing data for 10 patients with and 982 patients without SRC
  2. #Generalized Hodges-Lehmann median differences